Integrated Platform for In Vitro Culturing of Cells and Tissues

细胞和组织体外培养集成平台

• 批准号: 8586458
• 负责人: Colleen K Van Pelt
• 金额: $ 26.77万
• 依托单位: CORSOLUTIONS, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8586458
• 关键词: Address; Animals; Architecture; Area; Attention; Automation; Biological; Biomedical Research; Carbon Dioxide; Cardiovascular system; Cell Culture Techniques; Cell secretion; Cells; Chemicals; Clinical Trials; Coin; Culture Media; Cultured Cells; Development; Devices; Diffusion; Dimensions; Engineering; Environment; Evaluation; Future; Glues; Goals; Heating; Humidity; In Vitro; Incubators; Industry; Laboratories; Left; Liquid Chromatography; Liquid substance; Metabolic Control; Microfabrication; Microfluidic Microchips; Microfluidics; Microscope; Modeling; Names; Nutrient; Optics; Outcome; Patients; Pharmaceutical Preparations; Phase; Physiologic pulse; Property; Pump; Research; Research Personnel; Signal Transduction; Small Business Innovation Research Grant; Solutions; Staging; Surface; System; Techniques; Technology; Therapeutic; Tissues; Toxic effect; Toxicology; Training; Universities; arm; base; commercialization; complex biological systems; cost; design; detector; drug development; drug testing; flexibility; fluid flow; hospital laboratories; improved; in vitro Model; in vivo; in vivo Model; innovation; instrumentation; meetings; microchip; nano; novel; physical state; point of care; public health relevance; research and development; success; tissue/cell culture; user-friendly

DESCRIPTION (provided by applicant): The merging of cell culture and microfluidic technology has resulted in improved in vitro models for toxicity studies, drug development, and biomedical research. The reason for which microfluidic approaches provide a more accurate in vitro model of in vivo effects is because devices can be designed with unique properties to closely mimic the in vivo environment. Specifically the micrometer dimensions in the devices allow for a high surface area to volume ratio, leading to more effective nutrient transfer, and allowing a more in vivo-like cellular environment in terms of cell secretion and signaling. Furthermore there is no turbulence in the microchannels as fluid flow is laminar, allowing the only means of mass transport to be through diffusion, similar to a cell's natural environment. Consequently microfluidic approaches allow for biomolecular gradients to be imitated, and additionally microfluidic devices allow for 3D cell culture. Although much research has been performed in this exciting, emerging area, it nearly exclusively has focused on the microfluidic devices themselves, leaving the means of interfacing the technology with the macro-world largely ignored. As conventional, macro detectors and fluid pumps are proven, established technology, it is desirable for microfluidic approaches to employ these industry standards. And although many acknowledge that development of micro-to-macro interface technology is vital to the future of the field as well as to the commercial success of the technology, alarming little progress has been made. To date the rudimentary technique of gluing tubing to microchips for use in large, cumbersome incubators is the norm. Therefore CorSolutions proposes to develop and evaluate a universal platform, the CorCardio, to interface a wide variety of microfluidic devices to the macro-world. The platform will incorporate technology previously developed at CorSolutions including non-permanent, compression, fluidic interconnects and accurate, pulse-free fluid delivery pumps, with a heated insert design that will offer a simple alternative to an incubator. The proposed platform will be reliable, compatible with all substrate materials, easy to use with little training, flexible for use with chips having varied architectures, chemically compatible, allow for maximum field of view for optical assessment, leak-free over a wide-range of flow rates and backpressures, low cost, and have potential for automation. Thus the user-friendly platform will offer an interconnect solution with the potential of becoming the standard for "cells-on-a-chip" applications. This platform will allow for "cells-on-a- chip" applications to become pervasive in toxicology studies, lowering the high attrition rate of drugs in clinical trial while also limiting the number of animals needed for biomedical research. Furthermore the platform will allow for point-of-care applications, where patient-derived cells will permit individualized drug testing, improving therapeutic outcomes. In summary, the interconnect platform will assist in the commercialization of "cells-on-a- chip" applications, enabling scientifc breakthroughs and greater understanding of complex biological systems.

描述(申请人提供)：细胞培养和微流控技术的融合导致了毒性研究、药物开发和生物医学研究的体外模型的改进。微流控方法提供更准确的体内效应体外模型的原因是，设备可以设计成具有独特的特性，以接近体内环境。具体地说，设备中的微米尺寸允许高表面积与体积比，导致更有效的营养转移，并允许在细胞分泌和信号方面更接近体内的细胞环境。此外，微通道中没有湍流，因为流体流动是层流的，允许质量传输的唯一方式是通过扩散，类似于细胞的自然环境。因此，微流控方法允许模拟生物分子梯度，此外，微流控设备允许3D细胞培养。尽管在这个令人兴奋的新兴领域进行了许多研究，但几乎完全集中在微流控设备本身，而忽略了将该技术与宏观世界对接的手段。由于传统的宏观探测器和流体泵是公认的成熟技术，因此微流控方法采用这些行业标准是可取的。尽管许多人承认，微到宏观接口技术的发展对该领域的未来以及该技术的商业成功至关重要，但令人震惊的是，进展甚微。到目前为止，在大型、笨重的孵化器中使用的基本技术是将管子粘合到微芯片上。因此，CorSolutions建议开发和评估一个通用平台CorCardio，将各种微流控设备连接到宏观世界。该平台将融合之前在CorSolutions开发的技术，包括非永久性、压缩、流体互连和精确的无脉冲液体输送泵，以及加热插入物设计，将提供孵化器的简单替代方案。所提出的平台将是可靠的，与所有衬底材料兼容，易于 只需少量培训即可使用，可灵活地与具有不同架构的芯片一起使用，化学上兼容，允许进行光学评估的最大视野，在大范围的流速和背压范围内无泄漏，低成本，并具有自动化的潜力。因此，用户友好的平台将提供一种互连解决方案，有可能成为“芯片上的电池”应用的标准。该平台将允许“芯片上的电池”应用程序 在毒理学研究中变得普遍，降低了临床试验中药物的高磨损率，同时也限制了生物医学研究所需的动物数量。此外，该平台将允许使用护理点应用程序，其中患者来源的细胞将允许个性化的药物测试，从而改善治疗结果。总而言之，互连平台将有助于将“芯片上的细胞”应用商业化，使科学突破和对复杂生物系统的更好理解成为可能。